280 related articles for article (PubMed ID: 31896065)
1. IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway.
Cai H; Yan L; Liu N; Xu M; Cai H
Biomed Pharmacother; 2020 Mar; 123():109790. PubMed ID: 31896065
[TBL] [Abstract][Full Text] [Related]
2. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway" [Biomed. Pharmacother. 123 (2020) 109790].
Cai H; Yan L; Liu N; Xu M; Cai H
Biomed Pharmacother; 2020 Jun; 126():110077. PubMed ID: 32173085
[No Abstract] [Full Text] [Related]
4. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
Shi F; Su J; Wang J; Liu Z; Wang T
Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
[TBL] [Abstract][Full Text] [Related]
5. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.
Lv Y; Zhao Y; Wang X; Chen N; Mao F; Teng Y; Wang T; Peng L; Zhang J; Cheng P; Liu Y; Kong H; Chen W; Hao C; Han B; Ma Q; Zou Q; Chen J; Zhuang Y
J Immunother Cancer; 2019 Feb; 7(1):54. PubMed ID: 30808413
[TBL] [Abstract][Full Text] [Related]
6. USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF-κB/PD-L1 axis to promote the development of cervical cancer.
Li N; Geng F; Liang SM; Qin X
Cell Signal; 2022 Aug; 96():110351. PubMed ID: 35523402
[TBL] [Abstract][Full Text] [Related]
7. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
[TBL] [Abstract][Full Text] [Related]
8. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
9. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway.
Wang S; Li J; Xie J; Liu F; Duan Y; Wu Y; Huang S; He X; Wang Z; Wu X
Oncogene; 2018 Jul; 37(30):4164-4180. PubMed ID: 29706653
[TBL] [Abstract][Full Text] [Related]
10. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
[TBL] [Abstract][Full Text] [Related]
11. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
Jiang Y; Yuan Y; Chen M; Li S; Bai J; Zhang Y; Sun Y; Wang G; Xu H; Wang Z; Zheng Y; Nie H
Theranostics; 2021; 11(18):9162-9176. PubMed ID: 34522232
[No Abstract] [Full Text] [Related]
12. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
13. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Yang WH; Cha JH; Xia W; Lee HH; Chan LC; Wang YN; Hsu JL; Ren G; Hung MC
Cancer Res; 2018 Jul; 78(14):3761-3768. PubMed ID: 29789418
[TBL] [Abstract][Full Text] [Related]
14. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
15. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer.
Zhou L; Xu Q; Huang L; Jin J; Zuo X; Zhang Q; Ye L; Zhu S; Zhan P; Ren J; Lv T; Song Y
Cancer Lett; 2021 Mar; 500():163-171. PubMed ID: 33278498
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.
Ju X; Zhang H; Zhou Z; Chen M; Wang Q
Exp Cell Res; 2020 Nov; 396(2):112315. PubMed ID: 33031808
[TBL] [Abstract][Full Text] [Related]
17. Expressions of Immune Negative Regulator FoxP3+Treg and PD-L1 Protein in the Immune Microenvironment of Cervical Lesion.
Ma Q; Zhao M; Wei X; Zhao J; Yang T; Zhang Q; Wang K; Yang X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Feb; 39(1):128-132. PubMed ID: 28270295
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils.
Shang A; Wang W; Gu C; Chen C; Zeng B; Yang Y; Ji P; Sun J; Wu J; Lu W; Sun Z; Li D
J Exp Clin Cancer Res; 2019 Sep; 38(1):411. PubMed ID: 31533774
[TBL] [Abstract][Full Text] [Related]
19. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
[TBL] [Abstract][Full Text] [Related]
20. Formononetin Restrains Tumorigenesis of Breast Tumor by Restraining STING-NF-κB and Interfering with the Activation of PD-L1.
Liu H; Wang Z; Liu Z
Discov Med; 2024 Mar; 36(182):613-620. PubMed ID: 38531802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
